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I. INTRODUCTION
Pharmaceutical drugs are an extremely important part of
medical care and integral to maintaining a person’s health and
wellbeing. Given that most American citizens will have to purchase a
pharmaceutical during their lifetime, affordability is an important
issue that affects everyone. Pharmaceuticals are supposed to help
afflicted Americans, not harm them financially. A dilemma exists
when pharmaceuticals are prescribed as necessary to a person’s
medical care and treatment, but the person cannot afford to purchase
them. Pharmaceuticals in the United States should not be cost
prohibitive. How can we balance the interests of people who need
pharmaceuticals with the interests of pharmaceutical companies? The
answer is negotiation. However, this seemingly simple answer does
not come without complications. Medicare, the largest buyer of
brand-name prescription drugs in the United States, is not allowed to
negotiate with pharmaceutical companies. Therefore, this comment
will focus on Medicare’s inability to negotiate with pharmaceutical
companies.
This comment addresses the high price of brand-name
pharmaceuticals in the United States and suggests how the price of
pharmaceuticals can be lowered. This comment will compare the
United States’ system, that lacks price controls, to the systems
implemented in Canada and the United Kingdom. Both Canada and
the United Kingdom allow their governments to negotiate directly
with pharmaceutical companies. As a result, the price of brand-name
pharmaceuticals in Canada and the United Kingdom are drastically
lower than the price of brand-name pharmaceuticals in the United
States. In addition to negotiation, Canada and the United Kingdom
both regulate pharmaceutical prices. Canada regulates the maximum
price of the pharmaceuticals and the United Kingdom regulates the
amount of profit pharmaceuticals generate. This comment will argue
that the United States government should allow Medicare to
negotiate directly with brand-name pharmaceutical companies,
referencing both Canada and the United Kingdom as models for
regulating the prices of brand-name pharmaceuticals.
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This comment proceeds in seven parts. Part I of this
comment discusses the pricing of brand-name pharmaceuticals in the
United States. This discussion will include the history of Medicare,
the prohibition of Medicare directly negotiating with brand-name
pharmaceutical companies, Medicare’s purchasing process, and a
recent example of a brand-name pharmaceutical company increasing
the price of their pharmaceutical. Part II of this comment discusses
the impact high priced brand-name pharmaceuticals have on
consumers. Part III of this comment explains Canada’s approach to
setting prices for brand-name pharmaceuticals and Part IV explains
the approach taken by the United Kingdom when setting prices of
brand-name pharmaceuticals. Part V of this comment analyzes and
explains how allowing Medicare to negotiate directly with brandname pharmaceutical companies would decrease the price of brandname pharmaceuticals. This part of the comment also discusses what
processes the United States should implement and addresses
arguments against allowing Medicare to negotiate directly with brandname pharmaceutical companies. Part VI of this comment lists other
possible ways to lower pharmaceutical prices in the United States, but
explains why allowing Medicare to negotiate directly with brandname pharmaceutical companies would best achieve that goal. Part
VII summarizes and concludes the comment.
II. PHARMACEUTICAL SALES AND PRICING IN THE UNITED STATES
The price of brand-name pharmaceuticals in the United
States is higher than any other developed country in the world.1 In
order to grasp the severity of this problem, one must look to some
statistics. The International Federation of Health Plans found that
people in the United States pay two to six times more than the rest of
the world for brand-name pharmaceuticals.2 A Reuters analysis
showed that the United States pays as much as seven times more

Nadia Kounang, Why pharmaceuticals are cheaper abroad, CNN (Sept. 28,
2015, 8:46AM), www.cnn.com/2015/09/28/health/us-pays-more-for-drugs.
2
Id. (comparing the price of brand-name pharmaceuticals in the United
States to the price of brand-name pharmaceuticals in other countries).
1
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than the United Kingdom for some top-selling drugs.3 Prices for top
pharmaceuticals increased by 127 percent from 2008 to 2014.4
Pharmaceuticals are far outpacing inflation.5 Moreover, drug prices
have risen approximately 10 percent over a one-year period ending in
May 2016.6 The inflation rate at that time was only 1 percent.7 One
reason for the high prices is that Medicare cannot directly negotiate
prices with brand-name pharmaceutical companies. Medicare has
tremendous bargaining power to negotiate lower prices being that it
is the largest buyer of pharmaceuticals in the United States. Because
Medicare cannot negotiate, however, pharmaceutical companies place
outrageous price tags on their products. The Director of Memorial
Sloan Kettering’s Center for Health Policy and Outcomes said
pharmaceutical companies place high prices on pharmaceuticals
simply “because they can.”8
A. History of Medicare and Its Inability to Negotiate in the United
States
In 1965 the Social Security Act established a health insurance
program called Medicare.9 Medicare consists of four parts, Parts A, B,
C, and D.10 Medicare Part D was created by the Medicare
Carolyn Y. Johnson, Why America pays so much more for drugs, THE
WASHINGTON POST (Feb. 25, 2016), https://www.washingtonpost.com/news
/wonk/wp/2016/02/25/why-america-pays-so-much-more-for-drugs/.
4
Ben Hirschler, Americans Pay More For Drugs Than Anyone In The World,
THE HUFFINGTON POST (Oct. 12, 2015, 12:21 PM), https://www.huffingtonpost
.com/entry/americans-pay-more-for-drugs-than-anyone-in-the-world_us_561bd
a8fe4b0e66ad4c89449.
5
See Johnson, supra note 3.
6
Brad Tuttle, Prescription Drug Prices in America Are Rising Like No Other
Industry, TIME (July 14, 2016), http://time.com/money/4406167/prescriptiondrug-prices-increase-why/.
7
Id.
8
See Kounang, supra note 1 (explaining that brand-name pharmaceutical
companies place excessive prices on their products because “[w]e have no rational
system in the U.S. for managing prices of drugs”).
9
Social Security Amendments of 1965, Pub. L. No. 89-97, 79 Stat. 286
(1935) (amended 1965).
10
Part A covers medically necessary hospital, skilled nursing facility, home
health, and hospice care; Part B covers medically necessary doctor’s services such
as preventive care, outpatient services, x-rays, and laboratory tests; Part C is not a
3
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Prescription Drug, Improvement, and Modernization Act.11 It
amended Title XVIII of the Social Security Act to provide a
voluntary prescription drug benefit under Medicare.12 This federal law
was signed by President George W. Bush on December 8, 2003.13
The Medicare Prescription Drug, Improvement, and Modernization
Act prohibits Medicare from negotiating directly with pharmaceutical
companies.14
B. The Procedure Medicare Utilizes to Purchase Pharmaceuticals
Due to the Prohibition on Negotiating Directly with
Pharmaceutical Companies
The United States bars Medicare from negotiating for lower
prices with pharmaceutical companies.15 Part B and Part D of
Medicare deal with the prescription drug market.16 Part B determines
the price of drugs by the average sales price in the previous quarter.17
Prices under Part D are fixed through private prescription drug plans
negotiating with pharmaceutical companies.18 The prescription drug
plans then submit their bids to the Center for Medicare and Medicaid
Services (CMS), which determines the purchase price of the drug and
separate benefit, but rather it allows private health insurance companies to give
Medicare benefits; Part D provides outpatient prescription drug coverage and is
only provided through private insurance companies that have government
contracts. See What does Medicare cover (Parts A, B, C, and D)?, MEDICARE
INTERACTIVE, https://www.medicareinteractive.org/get-answers/introduction-tomedicare/explaining-medicare/what-does-medicare-cover-parts-a-b-c-and-d (last
visited Nov. 13, 2017).
11
Medicare Prescription Drug, Improvement, and Modernization Act of
2003, Pub. L. No. 108-173, 117 Stat. 2066 (2003).
12
Id.
13
Id.
14
Id.
15
Id.
16
What does Medicare cover (Parts A, B, C, and D)?, supra note 10.
17
John B. Kirkwood, Article, Buyer Power and Healthcare Prices, 91 WASH. L.
REV. 253, 262 (2016) (explaining that “Medicare is a price taker” due to a lack of
negotiating with pharmaceutical companies by stating “[i]n essence, what drug
companies charged the prior quarter determines what they can charge this
quarter”).
18
Id. (explaining how the price Medicare pays for brand-name
pharmaceuticals is set).

320

2018

A Prescription to Cure the High Cost of Pharmaceuticals

6:1

the price beneficiaries must pay.19 A Medicare beneficiary then joins
and pays premiums to a prescription drug plan to obtain prescription
drugs.20 Pharmaceutical companies also negotiate privately with
insurance companies and employers. Although the private
prescription drug plans can discount the price of the prescription
drugs, the discounts would be greater if the largest buyer, Medicare,
could negotiate with drug manufacturers.21 If Medicare was allowed
to negotiate directly with pharmaceutical companies, the prices would
decrease as a result of leverage gained from the threat of lost
business.
C. Recent Example of a High Priced Brand-name Pharmaceutical in
the United States
1. The EpiPen Price Increase
Recently, United States citizens have been outraged by the
increase in the price of EpiPen. The drug in EpiPen is epinephrine.22
EpiPens are injected into people who experience anaphylaxis, an
allergic reaction that causes airways to close.23 Over sixty million
Epipens have been dispensed from 1987 to May 2016, indicating that
there is a large demand for this drug in the United States.24 Mylan
Pharmaceuticals, the manufacturer of EpiPen, has increased the price

19
Joshua C. Snow, Note, Reducing Pharmaceutical Fraud: In Search of The
Cocktail Prescription, 41 PUB. CONT. L.J. 1027, 1030 (2012).
20
Id. at 1031 (citing Susan Adler Channick, The Medicare Prescription Drug
Improvement and Modernization Act of 2003: Will It Be Good Medicine for U.S. Health
Policy?, 14 ELDER L.J. 237, 246-48 (2006)).
21
See Kirkwood, supra note 17, at 269.
22
EpiPen is used to treat anaphylaxis which is a potentially life threatening
allergic reaction that can occur within a couple of minutes. Anaphylaxis can be
caused by allergens such as foods, insect bites, and medications. Anaphylaxis causes
skin irritation, swelling of the lips, tongue, and airways. See Frequently Asked
Questions, EPIPEN, https://www.epipen.com/about-epipen/faq (last visited Nov.
13, 2017).
23
Jana Kasperkevic, New York investigates EpiPen maker Mylan after price hike
of medication, THE GUARDIAN (Sept. 2, 2016), https://www.theguardian.com/
business/2016/sep/06/epipen-price-hike-mylan-new-york-investigation.
24
Frequently Asked Questions, supra note 22, (“EpiPen Auto-Injector has
been available for more than 25 years.”).
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of this allergy medication by 471 percent since 2007.25 The cost of
Epipen recently rose from $100 to more than $600.26 Citizens are
worried about this drastic price increase because families often have
to purchase multiple EpiPens to keep in different locations such as at
school and home.27 Additionally, like other drugs EpiPens have an
expiration date and must be refilled before they expire.28 Therefore, if
the EpiPen is not used before it expires, the money paid for it is
essentially lost.
2. Americans Turn to Canada
A number of Americans have turned to Canada for lower
priced EpiPens.29 According to the general manager of the Canadian
International Pharmaceutical Association, the price of a single
EpiPen in Canada ranges from $100 to $145.30 This difference in
price is substantial. The price of EpiPen in Canada is approximately
$500 cheaper than the price of EpiPen in the United States.
Therefore, a number of Americans have purchased EpiPen from
Canadian online pharmacies to avoid high prices in the United
States.31
3. Mylan Pharmaceuticals’ Solution to the Price Increase
Mylan Pharmaceuticals, the manufacturer of EpiPen,
responded to the outrage by saying they would offer discounts to
customers.32 Mylan Pharmaceuticals’ short-term solution to satisfy
customers is to offer coupons for up to $300 to patients who face
In 2007 Mylan acquired EpiPen. Id.
Gillian Mohney, EpiPen Price Hike Prompts Some US Families to Buy the
Drug in Canada, ABC NEWS (Aug. 31, 2016, 12:30 PM), http://abcnews.go.com
/Health/epipen-price-hike-prompts-us-families-buy-drug/story?id=41769704.
27
Id. (stating that one woman used to keep three or even four EpiPen
packs in different areas when her son was a child).
28
Frequently Asked Questions, supra note 22.
29
See Mohney, supra note 26.
30
Id.
31
Id.
32
Nathan Bomey, EpiPen Maker to offer discounts after price hike firestorm, USA
TODAY (Aug. 26, 2016, 7:43 AM), http://www.usatoday.com/story/money
/2016/08/25/epipen-maker-offer-discounts-after-firestorm/89329122/.
25
26
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high out-of-pocket costs.33 Additionally, Mylan Pharmaceuticals
stated that they planned to make a generic version of EpiPen so
people would not have to pay for the expensive brand-name
EpiPen.34 However, there is currently no generic or brand name drug
that is similar to EpiPen.35
The Chairman of the House Oversight and Government
Reform Committee wrote a letter to the CEO of Mylan
Pharmaceuticals. He stated that Mylan has a monopoly over the
EpiPen market and their command of the market has given Mylan
the ability to charge any price they want for EpiPen.36 The
unfortunate result is that consumers must pay the high prices for
pharmaceuticals or go without their medication.

33
Id. (“Mylan also said it would double the income level at which families
are eligible for assistance in purchasing the medication to 400% of the federal
poverty level, which stands at $24,300 for a family of four.”).
34
The price of the generic EpiPen will cost approximately $300 for a two
pack. A mother who purchases EpiPen for her child was interviewed by ABC
News and said the generic price could still be prohibitive to many families. See
Mohney, supra note 26.
35
There is no generic substitute to EpiPen which means that people in
need of that medication have no other option for proper treatment. They must
purchase the brand-name EpiPen in order to receive the treatment they need. See
Bomey, supra note 32.
36
Letter from Jason Chaffetz, House Oversight and Government Reform
Committee Chairman to Heather Bresch, Chief Executive Officer of Mylan, Inc.
(Aug. 29, 2016), http://democrats.oversight.house.gov/sites/democrats.oversight
.house.gov/files/documents/2016-08-29%20JC%20and%20EEC%20%20to%20
Bresch- Mylan%20EpiPen%20Pricing.pdf, (“Mylan has a virtual monopoly over
the epinephrine auto-injector market. A national dependence on accessibility to
EpiPens has been well established since Mylan’s acquisition of the device in 2007.
This command of the market has given Mylan the unbridled ability to increase the
price of the two-pack EpiPen.”); see also Brad Tuttle, Prescription Drug Prices in
America Are Rising Like No Other Industry, TIME (July 14, 2016), http://time.com
/money/4406167/prescription-drug-prices-increase-why/(stating medication is
essential so people have little choice but to buy them no matter how much they
cost).
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III. THE CONSEQUENCES OF HIGH PHARMACEUTICAL PRICES
The EpiPen example is largely demonstrative of the current
pharmaceutical market in the United States. The price of
pharmaceuticals in the United States is often a large barrier for
people in need of treatment. Consumers of pharmaceuticals in the
United States often have to decide whether to fill their prescriptions
or buy other daily necessities such as food. Some individuals have to
decide whether to go bankrupt and obtain their medication or forego
their medicine altogether.37 Pharmaceuticals can be cost prohibitive.
It is a regular occurrence for people to not fill their prescriptions
once they find out the price, and thus sacrifice the treatment they
need. Experts estimate that approximately 20 percent of prescribed
medications are never filled.38 While there are other reasons that
patients do not take or fill their prescriptions, such as side effects and
lack of symptoms, the biggest reason is the cost of prescriptions.39
Pharmaceuticals are essential to a patient’s health and in extreme
situations a patient could die from not taking their prescriptions.40
Therefore, the people of the United States must pay a high price for

Brendan Murphy, Note, Getting High on Profits: An Analysis of Current State
and Federal Proposals to Rein in Soaring Drug Prices, 12 J. HEALTH & BIOMED. L. 37, 645 (2016) (citing Lee Graczyk, Americans can’t afford U.S. medication, need a safe alternative
(Nov. 12, 2014), http://thehill.com/blogs/congress-blog/healthcare/223650americans-cant-afford-us-medication-need-a-safe-alternative).
38
Christina Sumners, Why People Aren’t Taking Their Prescription Medications,
VITAL RECORD (Mar. 31, 2016), https://vitalrecord.tamhsc.edu/medication-nonadherence-people-arent-taking-prescription-medications/(explaining that nonadherence means patients willfully refusing to do what they should); Id. (“One of
the aspects of non-adherence is when the patient doesn’t take prescribed drugs
according to the provider’s instructions. This non-adherence leads to
hospitalizations when chronic conditions flare up, and these hospitalizations cost
the health care system between $100 billion and $289 billion each year.”).
39
Id. (explaining that even though there are a number of other reasons
why a person will not get the pharmaceuticals they need price is the largest
deterrent); see also Pauline W. Chen, When Patients Don’t Fill Their Prescriptions, THE
NEW YORK TIMES (May 20, 2010), http://www.nytimes.com/2010/05/20/
health/20chen.html (explaining patient nonadherence and stating among other
reasons affordability is an important factor contributing to nonadherence).
40
Id. (“Failure to follow prescriptions causes some 125,000 deaths a year
and up to 10 percent of all hospitalizations.”).
37
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brand-name pharmaceuticals or take a high risk of making their
situations worse.
IV. PHARMACEUTICAL PRICING IN CANADA
Canada has significantly lower pharmaceutical drug prices
than the United States. In 1987, Canada put the Patented Medicines
Review Board in place through amendments to the Patent Act in
response to the North American Free Trade Agreement.41 The
Canadian federal government set up the Patented Medicine Prices
Review Board (PMPRB).42 The PMPRB has a dual regulatory and
reporting mandate.43 The Patented Medicine Prices Review Board
regulates the price of patented drugs to ensure that the prices are not
excessive.44 The PMPRB is made up of Board “Staff” and Board
“Members.”45 The Staff carries out the daily work and is responsible
for reviewing prices charged for all patented drugs sold in Canada.46
If a price is found to be excessive, the Staff will try to resolve the
issue with the patented drug company, but if the price issue is not
resolved, the Board Members may hold a hearing.47 The Members are
Mandate and Jurisdiction, CANADA PATENTED MEDICAL PRICES REVIEW
BOARD,
http://pmprb-cepmb.gc.ca/about-us/mandate-and-jurisdiction
(last
visited Nov. 13, 2017).
42
Id.
43
Strategic Plan 2015-2018: The Role of the PMPRB, CANADA PATENTED
MEDICAL PRICES REVIEW BOARD, http://www.pmprb-cepmb.gc.ca/view.asp
?ccid=1197#a11 (last visited Nov. 13, 2017), (explaining that the reporting
mandate requires the PMPRB to report to Parliament annually on its price reviews
activities, the prices of patented medicines and price trends, and on Research and
Development expenditures).
44
Id. (explaining that the PMPRB “operates independently of Health
Canada, which approves drugs for safety and efficacy; other health Portfolio
members, such as the Public Health Agency of Canada, and the Canadian Institute
for Health Research; and provincial drug plans, which approve the listing of drugs
on their respective formularies for reimbursement purposes”).
45
Id.
46
Id.
47
Strategic Plan 2015-2018: The Hearing Process, CANADA PATENTED
MEDICAL PRICES REVIEW BOARD, http://www.pmprb-cepmb.gc.ca/en/hearings
/the-hearing-process (last visited Nov. 13, 2017) (explaining that at a hearing the
Board acts as a neutral arbiter between parties before the Board, principally the
Board Staff and the patentee).
41
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appointed by the Governor-in-Council and are responsible for
conducting hearings when a price is allegedly excessive.48 The Board
Members have the power to reduce the price of the patented drug or
order the patented drug company to offset excess revenues, if they
find that the price is excessive.49
Canada’s system is different from that of other countries
because they do not have a national purchasing authority to buy
patented drugs for the entire population.50 Instead, the PMPRB sets
price ceilings for all patented drugs.51 The Patented Medicine Prices
Review Board takes several factors into account when setting these
ceilings, including the level of therapeutic improvement, domestic
prices, prices in seven countries, and changes in the Consumer Price
Index.52
Nevertheless, Canada’s system of pharmaceutical price
controls is not without flaws.53 The largest flaw of Canada’s pricing
system is that it looks at the sticker prices of the same brand-name
pharmaceuticals in other countries.54 Canada, looking at the sticker
Id.
Patented Medicine Prices Review Board, GOVERNMENT OF CANADA,
https://www.canada.ca/en/patented-medicine-prices-review.html (last visited
Nov. 13, 2017).
50
Strategic Plan 2015-2018: The Pharmaceutical Environment in Canada,
CANADA PATENTED MEDICAL PRICES REVIEW BOARD, http://www.pmprbcepmb.gc.ca/view.asp?ccid=1197#a11, (last visited Nov. 13, 2017).
51
Id.
52
The countries Canada compares their pharmaceutical prices with are
France, Germany, Italy, Sweden, Switzerland, the United Kingdom, and the United
States. Id.
53
See generally Karen L. Tang, William A. Ghali, & Braden J. Manns,
Addressing cost-related barriers to prescription drug use in Canada, 186(4) CMAJ :
CANADIAN MEDICAL ASSOCIATION JOURNAL. 276, 276-280 (2014) (explaining that
the Patented Medicine Review Board currently compares prices to countries with
some of the highest drug prices worldwide and they should instead compare to
countries with lower prices in order to lower brand-name pharmaceutical prices in
Canada).
54
Brendan Murphy, Note: Getting High on Profits: An Analysis of Current State
and Federal Proposals to Rein in Soaring Drug Prices, 12 J. HEALTH & BIOMED. L. 37, 84
(2016) (citing Sean Davidson, Drug Price Regulations Need Overhaul to Protect Consumers,
Experts Say, CBC.CA (Sept. 23, 2015), http://www.cbc.ca/news/health/
48
49
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prices of brand-name pharmaceuticals in other countries for
comparison, does not take into account the final price the country
pays for the pharmaceutical.55 In other words, Canada does not take
into account the rebates other countries receive from brand-name
pharmaceutical companies.56 Therefore, the price Canada refers to is
not the final price that other countries pay for the brand-name
pharmaceutical. Considering other countries’ pre-rebate prices, leads
to Canadians paying higher prices than the other countries do for the
same brand-name pharmaceuticals.57
V. PHARMACEUTICAL PRICING IN THE UNITED KINGDOM
In the United Kingdom, the Pharmaceutical Price Regulation
Scheme (PPRS) has been in existence since 1957.58 In the United
Kingdom, the prices of brand-name pharmaceuticals supplied to the
National Health Service (NHS) are regulated by either a voluntary
agreement or by the Health Service Branded Medicines Regulations.59
The voluntary agreement, the Pharmaceutical Price Regulation
Scheme (PPRS), is between the Department of Health and the
Association of the British Pharmaceutical Industry (ABPI), which
deals with the supply of branded drugs to the National Health
Service.60 The agreement is normally negotiated for a period of five

prescription-drug-prices-1.3239317 (discussing that drug prices for patented drugs
are calculated using a median average of prices from other countries, comparing
Canada’s pharmaceutical price regulations to other countries and assessing the
impact of the disparities between them).
55
Id.
56
A rebate is a “return of a portion of a purchase price by a seller to a
buyer, usually on purchase of a specified quantity, or value, of goods within a
specified period. Unlike discount (which is deducted in advance of payment), rebate
is given after the payment of full invoice amount.” Rebate, DICTIONARY.COM,
http://www.dictionary.com/browse/rebate (last visited Nov. 13, 2017).
57
See Murphy, supra note 54.
58
Understanding the 2014 Pharmaceutical Price Regulation Scheme, THE
ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY, http://www.abpi.
org.uk/our-work/policyparliamentary/ Documents/understand ing_pprs2014.pdf
(last visited Nov. 13, 2017).
59
Id.
60
Id.
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years and then renegotiated thereafter.61 The current scheme is the
2014 Pharmaceutical Price Regulation Scheme, which became
effective on January 1, 2014.62 The agreement regulates the profit that
brand-name drug companies can generate, instead of regulating the
price of the drugs directly, like some other countries do.63 Any brandname pharmaceutical company that supplies the NHS with
pharmaceuticals can participate in this scheme.64
Simply stated, the Pharmaceutical Price Regulatory Scheme
regulates the cost of the brand-name pharmaceuticals by limiting the
amount of profit pharmaceutical companies may generate.65
Pharmaceuticals are then allocated domestically in the United
Kingdom through the National Health Service. If pharmaceutical
companies are not satisfied with the price negotiated by the
Pharmaceutical Price Regulatory Scheme, they can sell their
pharmaceuticals privately. Pharmaceutical companies who chose to
sell their pharmaceuticals privately automatically fall under the
Statutory Scheme which imposes a list price cut of 15 percent on all
products.66 Even though membership to the Pharmaceutical Price
Regulatory Scheme is voluntary, most pharmaceutical companies

Id. (explaining that the PPRS is usually negotiated for a period of five
years, but has often lasted longer than five years and has only once been terminated
before the agreement was to expire).
62
The 2014 Pharmaceutical Price Regulation Scheme will terminate on
December 31, 2018. Id.
63
Murphy, supra note 54 (“It regulates the profit that companies can
achieve on sales to the NHS, rather than regulating prices directly. However, it
does not guarantee profit. Instead, it is based on a range of maximum allowances
covering R&D, manufacturing costs, information, sales and marketing, and general
administrative costs. These are then subject to a maximum percentage profit. The
underlying assessment of profit remains the core basis of the 2014 PPRS.”).
64
Pharmaceutical companies who choose not to participate in the PPRS
are regulated by a different set of statues. Id. at 4.
65
Id.
66
Aurelie Mahalatchimy, Reimbursement of cell-based regenerative therapy in the
UK and France, 24(2) MED. LAW REV. 234, 234 (2016) (citing The Health Service
Medicines (Control of Prices and Supply of Information) (Amendment)
Regulations 2013, Statutory Instrument No. 2881) (explaining the scheme
pharmaceutical companies follow when they do not participate in voluntary
negotiations).
61
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choose to join.67 The purpose of the Scheme is to ensure that safe
and effective pharmaceuticals are available on reasonable terms with
the NHS and to maintain a strong, efficient, and profitable
pharmaceutical industry.68
VI. ALLOWING MEDICARE TO NEGOTIATE DIRECTLY WITH
PHARMACEUTICAL COMPANIES
A. Explanation of How Negotiation Would Lower Pharmaceutical
Prices
Allowing Medicare to negotiate directly with pharmaceutical
companies is the most effective way to lower the price of
pharmaceuticals. Medicare would be able to lower pharmaceutical
prices through negotiation because all developed countries that allow
negotiation with pharmaceutical companies pay lower prices for
pharmaceuticals than the United States. As previously stated,
Medicare is the largest purchaser of prescription drugs in the United
States.69 This gives Medicare significant bargaining power to negotiate
price with pharmaceutical companies. Bargaining power in
negotiations is the ability of one party to dominate the other due to
its influence, power, size, status, or through a combination of other
different persuasion tactics.70
Moreover, pharmaceutical companies would lower their
prices if Medicare negotiated with them because the pharmaceutical
companies have an incentive to keep Medicare as a customer.
Pharmaceutical companies would lower the price of their
pharmaceuticals because there would be a threat of lost business if
Medicare did not buy their pharmaceuticals due to the price. If
Medicare walked away from a deal because the price of the
pharmaceutical was too high, pharmaceutical companies would not
Id.
Understanding the 2014 Pharmaceutical Price Regulation Scheme, supra note 58.
69
Jeanne Whalen, Why the U.S. Pays More Than Other Countries for Drugs,
THE WALL STREET JOURNAL (DEC. 1, 2015, 9:27 PM), https://www.wsj
.com/articles/why-the-u-s-pays-more-than-other-countries-for-drugs-1448939481.
70
Bargaining Power, BUSINESS DICTIONARY, http://www.businessdictionary
.com/definition/bargaining-power.html (last visited Nov. 13, 2017).
67
68
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make any profit. Additionally, pharmaceutical companies would have
to find more buyers for their product in an attempt to make up for
the lost business of the largest purchaser in the industry. This would
prove to be time consuming and use more of the companies’
resources. Therefore, it follows that pharmaceutical companies would
likely lower the price of pharmaceuticals because a decrease in profit
is better than making no profit at all. These pharmaceutical
companies could lower their prices to a point where they could still
make a profit while making the price attractive to Medicare. The
additional business the pharmaceutical companies would receive
from Medicare in the future, would justify the reduction in price.
In addition, pharmaceutical companies can still retain their
bargaining power. The Centers for Medicare and Medicaid Services
(CMS) force prescription drug plans (PDPs) to cover almost all drugs
in certain categories.71 This requirement has a number of effects on
the negotiation process.72 This gives pharmaceutical companies
bargaining power because Medicare would not be able to walk away
from a deal if they are required to cover the drug. Additionally, this
requirement protects consumers. Consumers would not have to fear
that a brand-name pharmaceutical they need will not be covered
because of Medicare’s ability to negotiate with pharmaceutical
companies. If Medicare is required to cover a drug, it has no choice
but to purchase the drug.
However, this will only be the case if only one or two drugs
are offered on the market. If there are multiple drugs on the market,
Medicare can choose to obtain a lower price on a substitute from a
pharmaceutical competitor. This will encourage competition among
pharmaceutical companies competing for Medicare’s business. This
competition between pharmaceutical companies would cause the
71
Report to Congress: Medicare Payment Policy, MEDICARE PAYMENT
ADVISORY COMMISSION at 401, (March 23, 2016), http://medpac.gov/docs/
default-source/reports/mar17_entirereport.pdf (explaining “[f]or six drug classes,
CMS requires Part D plans to cover “all or substantially all” drugs in the class
(protected class)”).
72
Id. (“This policy is intended to allow competition in classes with multiple
products while protecting beneficiaries who need a drug that is the only one
available to treat a certain condition.”).
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pharmaceutical companies to lower their prices so Medicare will buy
their product and not their competitor’s product.
B. Canada and the United Kingdom as a Model for Pharmaceutical
Pricing
The United States should implement a pharmaceutical pricing
system, that models parts of the systems currently in place in Canada
and in the United Kingdom, to negotiate and set brand-name
pharmaceutical prices. The United States should allow brand-name
pharmaceutical companies to choose whether or not they want to
negotiate with Medicare, just as the United Kingdom allows
pharmaceutical companies to choose whether or not they want to
participate in the Pharmaceutical Price Regulation Scheme (PPRS).73
Further, if certain brand-name pharmaceutical companies choose not
to negotiate with Medicare, they would be subject to pricing
regulations. This mirrors the United Kingdom’s system wherein
pharmaceutical companies that do not participate in the
Pharmaceutical Price Regulation Scheme are subject to separate
regulations.74
The United Kingdom regulates the amount of profit brandname pharmaceutical companies can generate rather than setting a
cap on the price of the pharmaceutical.75 The United States should
implement a regulation regime similar to the United Kingdom’s. This
method ensures that brand-name pharmaceutical companies are
generating a profit and not just covering their costs.76 It is important
that brand-name pharmaceutical companies continue to realize a
profit or they would stop manufacturing the pharmaceuticals to avoid

73
See Murphy, supra note 54. (prices of brand-name pharmaceuticals
supplied to the National Health Service (NHS) are regulated by either a voluntary
agreement, or the Health Service Branded Medicines Regulations).
74
Understanding the 2014 Pharmaceutical Price Regulation Scheme, supra note 58.
75
Id.
76
Id. (explaining that the United Kingdom’s Pharmaceutical Price
Regulation Scheme allows companies to make a reasonable profit to enable them to
continue investing in the development of new pharmaceuticals and setting a limit
on profit helps secure value for money for the NHS).
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losses.77 Moreover, regulating the profit rather than the final price of
a pharmaceutical would aid in safeguarding the profitability of the
pharmaceutical companies.
Regulating the profit a pharmaceutical company could
generate, would reduce the price of pharmaceuticals. For example, if
a brand-name pharmaceutical company was only permitted to
generate $1 of profit on each pharmaceutical sold and the cost of
production was $1, the price of the pharmaceutical could not exceed
$2. The United Kingdom’s Scheme recognizes the importance of
balancing the interests of the pharmaceutical industry and the
interests of patients.78 The United States should regulate profit like
the United Kingdom does because it strikes the needed balance
between the interests of brand-name pharmaceutical companies, that
are in business to make profit, and the interests of the citizens, who
need the pharmaceuticals to remain in good health.
The United States should also put a board in place to be
responsible for setting a cap, or limit, on the amount of profit brandname pharmaceutical companies could generate if they chose not to
negotiate with Medicare. The Canadian federal government set up the
Patented Medicine Prices Review Board, which is responsible for
overseeing the prices of brand-name pharmaceuticals and ensuring
that the prices are not excessive.79 The United States should create a
board similar to Canada’s Board. This board could consider a range
of factors when setting the cap on the amount of profit brand-name
pharmaceutical companies could generate from their pharmaceuticals.
The United States board could consider factors that are similar to the
factors Canada’s Patented Medicine Prices Review Board considers
Although discovering new drugs is important to pharmaceutical
companies there must be a potential to make profit. “People invest in areas where
they can get a return on their investment. An area . . . which offers no possible
return on investment would be summarily dismissed.” John LaMattina, ‘Do Drug
Companies Make Drugs, Or Money?’, FORBES (July 29, 2014, 9:03AM),
http://www.forbes.com/sites/johnlamattina/2014/07/29/do-drug-companiesmake-drugs-or-money/#237b8db47fcf.
78
Understanding the 2014 Pharmaceutical Price Regulation Scheme, supra note 58
(stating “The PPRS recognizes the importance of striking a balance to promote the
common interests of patients, the NHS, the industry and the taxpayer”).
79
Strategic Plan 2015-2018: The Role of the PMPRB, supra note 43.
77
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when determining the price ceiling for pharmaceuticals. The Patented
Medicine Prices Review Board takes several factors into account
when setting the price ceiling, including the level of therapeutic
improvement, domestic prices, prices in seven other countries, and
changes in the Consumer Price Index.80
As a cautionary note, the United States should learn from the
flaws in Canada’s system and consider the price of pharmaceuticals in
other countries after rebates. The United States should not merely
look at the sticker price of the pharmaceuticals in other countries as
Canada does because that sticker price decreases after rebates.
C. Arguments Against Medicare Negotiating with Brand-name
Pharmaceutical Companies
It is argued that Medicare should not be allowed to directly
negotiate with pharmaceutical companies. One of the main
arguments is that it will adversely impact research and development
(R&D).81 It is argued that if Medicare was allowed to negotiate with
pharmaceutical companies, the price of the company’s product would
fall and as a result they would have less money to advance research
and development. As a consequence of less research and
development, fewer drugs would be brought to market.
Pharmaceutical Research and Manufacturers of America (PhRMA)
argues that high pharmaceutical prices are due to the cost of research
and development to bring a new drug to market.82 Many drugs do not
even make it to the market.83 PhRMA claims that it takes

80

Strategic Plan 2015-2018: The Pharmaceutical Environment in Canada, supra

note 50.
81
See Joseph Gulfo, Medicare negotiating with pharma is not the answer, THE
HILL (Dec. 4, 2015, 7:00 AM), http://thehill.com/blogs/punditsblog/healthcare/262077-medicare-negotiating-with-pharma-is-not-the-answer.
82
See Kounang, supra note 1.
83
California Biomedical Research Association, Fact Sheet: New Drug
Development Process, CALIFORNIA BIOMEDICAL RESEARCH ASSOCIATION, http://
www.ca-biomed.org/pdf/media-kit/fact-sheets/FS-DrugDevelop.pdf (last visited
Nov. 13, 2017) (explaining that it takes approximately 12 years for a drug to make it
to the patient, and only 1 in 5,000 drugs are approved for patient usage); see also
Drug Approvals- From Invention to Market . . . A 12- Year Trip, MEDICALNET.COM,
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approximately ten years and around two and a half billion dollars to
bring a new drug to the market.84
However, lower pharmaceutical prices will not necessarily
decrease research and development in pharmaceuticals. Past research
and development costs are not very relevant to the present price of
the pharmaceutical because the price is determined by the demand
for the pharmaceutical.85 Further, the prices charged for
pharmaceuticals are the prices the market will bear.86 Although some
costs of research and development are passed to the buyer,
pharmaceutical companies also share the expense and consider it a
sunk cost.87 Healthcare America Now explained that research and
development would not suffer as a result of lower pharmaceutical
prices because, from 1998 to 2007, half of the innovative drugs
approved resulted from research done by universities and biotech
firms, not pharmaceutical companies.88
In addition, pharmaceutical companies spend nineteen times
more on marketing their products than on research and
http://www.medicinenet.com/script/main/art.asp?articlekey=9877 (last visited
Nov. 13, 2017).
84
See Kounang, supra note 1.
85
Tomas Philipson, Why the Drug Industry and Its Critics Are Both Wrong
About How R&D Spending Affects Pricing, FORBES (Oct. 6, 2016),
http://www.forbes.com/sites/tomasphilipson/2016/10/06/why-the-drugindustry-and-its-critics-are-both-wrong-about-how-rd-spending-affectspricing/#cb5980df9818 (explaining that past research and development costs
should not be given great weigh when setting the price of a brand-name
pharmaceutical, instead the prices of the brand-name pharmaceuticals drive
Research and Development spending).
86
Id.
87
See Sunk cost, BUSINESS DICTIONARY, http://www.business dictionary
.com/definition/sunk-cost.html (last visited Nov. 13, 2017) (“Money already spent
and permanently lost. Sunk costs are pat opportunity costs that are partially (as
salvage, if any) or totally irretrievable and, therefore, should be considered
irrelevant to future decision making . . . Also called embedded cost, prior year cost,
standard cost, or sunk capital.”).
88
Legislative Brief Why Can’t Medicare Negotiate Drug Prices with Pharmaceutical
Companies?, OHIO COUNCIL OF CHURCHES (October 18, 2016), http://diosohio
.org/ publicpolicy/why-cant-medicare-negotiate-drug-prices-with-pharmaceuticalcompanies/.
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development.89 This high marketing cost shows that pharmaceutical
companies have the ability to maintain the same level of research and
development and cut costs in other areas. Additionally, the profit
generated by pharmaceutical companies is not likely to fall when the
pharmaceuticals do not have a substitute. Furthermore, if there are
no other competitors on the market, Medicare would be forced to
purchase the new pharmaceutical and the pharmaceutical companies
would generate a large return on their research and development.
This creates an incentive for pharmaceutical companies to invest in
research and development and be the first company to bring a
pharmaceutical to the market. As the first to bring a pharmaceutical
to the market, profits will be high as a result of market dominance.
Others argue that Medicare negotiating directly with brandname pharmaceutical companies would be impractical.90 The
argument is that it would not be practical for the Centers for
Medicare and Medicaid Services to negotiate the prices of
pharmaceuticals because the process would be extremely time
consuming and expensive.91 However, this argument is not persuasive
because the benefit of lower prices of pharmaceuticals greatly
outweighs the time and expense of the negotiations. Further, the
Food and Drug Administration (FDA) must examine all
pharmaceuticals before they reach the market.92 Even though it takes
the FDA some time to examine all of the pharmaceuticals, it is seen
as worthwhile. The same logic follows for allowing Medicare to
negotiate with pharmaceutical companies. Although it could be a
lengthy process, it would be worthwhile.
Finally, critics argue that allowing Medicare to negotiate
directly with pharmaceutical companies will simply not lower the
89
Id. (explaining that although pharmaceutical companies strongly argue
attempts to lower prices would kill their research and development, pharmaceutical
companies spend a lot more money in other areas such as marketing).
90
David Nather, Washington has big hopes, but little power, to negotiate drug prices,
STAT NEWS (Jan. 6, 2016), https://www.statnews.com/2016/01/06/medicarenegotiate-drug-prices.
91
Id.
92
Development & Approval Process (Drugs), U.S. FOOD AND DRUG
ADMINISTRATION, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
(last visited Nov. 13, 2017).
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price of pharmaceuticals.93 It is argued that Medicare will not be able
to reduce the price of pharmaceuticals because they do not have the
ability to reject a pharmaceutical.94 They argue that because Congress
put rules in place to strengthen pharmaceutical companies’
negotiations, the need for Medicare to negotiate is unnecessary to
lower prices.95 Essentially the price of pharmaceuticals will not
decrease, even if Medicare was allowed to negotiate with
pharmaceutical companies, because Medicare does not have the
ability to refuse to buy the drug.
However, this argument only applies in situations when there
are only one or two drugs on the market. When there are multiple
competitors in the market, Medicare would have the leverage
stemming from the option to buy a competitor’s pharmaceutical. The
threat of Medicare saying no and buying a competitor’s product
would motivate a company to lower the price of their pharmaceutical
so they do not lose a major buyer.
Additionally, this argument does not favor prohibiting
Medicare from negotiating directly with pharmaceutical companies.
This argument merely identifies a step that is required in order for
Medicare to effectively negotiate with pharmaceutical companies.
Medicare must be allowed to say no to a pharmaceutical company
otherwise the use of their bargaining power would be to no avail. The
threat of not buying a pharmaceutical must be real in order to
negotiate lower prices.
The United States currently has a government program in
place that is allowed to negotiate with pharmaceutical companies and
refuse to buy the pharmaceutical, the Department of Veterans

93
Margot Sanger-Katz, The Real Reason Medicare Is a Lousy Drug Negotiator: It
Can’t Say No, THE NEW YORK TIMES (Feb. 2, 2016), http://www.nytimes
.com/2016/02/02/upshot/the-real-reason-medicare-is-a-lousy-drug-negotiator-itcant-say-no.html?_r=0.
94
Id.
95
Id. (explaining that Medicare must cover most pharmaceuticals and
would need to be bound by fewer rules and have the ability to say no to
pharmaceutical companies which would result in less drugs being covered by
Medicare).
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Affairs.96 The Veterans Administration offers a drug benefit with
lower costs than Medicare beneficiaries receive. The Veteran’s
Administration imposes price ceilings on some drugs and also
negotiates with pharmaceutical companies for discounts.97 This
demonstrates that it is possible to allow Medicare to refuse to buy a
drug from pharmaceutical companies. Therefore, the argument is
unfounded.
VII. OTHER SUGGESTED REFORMS TO LOWER THE COST OF
PHARMACEUTICALS
There are multiple other reform proposals suggested to lower
the prices of pharmaceuticals in the United States, including
increasing the number of generic pharmaceuticals and importing
pharmaceuticals from foreign countries.98 However, these proposals
would not be as effective in lowering pharmaceutical prices as
allowing Medicare to negotiate directly with pharmaceutical
companies.
It is argued that increasing the number of generic
pharmaceuticals on the market will cause pharmaceutical prices to
drop. A generic drug is a drug that is comparable to a brand-name
drug in dosage, strength, administration, quality, and performance.99
In the United States nearly 8 to 10 prescriptions filled are for generic
drugs.100 Additionally, research shows that generics work as well as

Id.
John E. Dicken, Prescription Drugs: An Overview of Approaches to Negotiate
Drug Prices Used by Other Countries and U.S. Private Payors and Federal Programs,
Testimony before the United States Senate, GAO-07-358T (Jan. 11, 2007).
98
See generally Paula Tironi, Article: Pharmaceutical Pricing: A Review of Proposals
to Improve Access and Affordability of Prescription Drugs, 19 ANN. HEALTH L. 311 (2010).
99
Abbreviated New Drug Application (ANDA), U.S. FOOD AND DRUG
ADMINISTRATION, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDr
ugApplicationANDAGenerics/default.htm (last visited Nov. 13, 2017).
100
Generic Drugs Facts, U.S. FOOD AND DRUG ADMINISTRATION,
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicine
Safely/UnderstandingGenericDrugs/ucm167991.htm (last visited Nov. 13, 2017).
96
97
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brand-name pharmaceuticals.101 However, innovators of new
pharmaceuticals obtain patents to protect their product from being
duplicated.102 The owner of a patent can exclude anyone from
making, using, offering for sale, or selling their invention for twenty
years from the filing of the patent application.103 This means that
generic pharmaceuticals cannot be released into the market until the
innovator’s patent expires. Therefore, increasing the number of
generic pharmaceuticals cannot happen until the patent expires,
which defeats this proposal.
Additionally, when the patents of brand-name pharmaceutical
companies’ expire, they often pay generic pharmaceutical
manufacturers to wait to release their generic version.104 This is
referred to as “pay for delay.”105 These pay for delay deals are made
so brand-name pharmaceutical companies can continue to generate
profits with no competition on the market.106 These transactions are
attractive to generic pharmaceutical companies because the money
they receive from the brand-name pharmaceutical companies replaces
the profit they would have made from the sales of their product. The
FDA also needs to approve the generic pharmaceutical before it goes
to market, which is a very lengthy process.107 The slow pace of the
Id. (“A study evaluated the results of 38 clinical trials that compared
cardiovascular generic drugs to their brand-name counterparts. There was no
evidence that brand-name heart drugs worked any better than generic heart
drugs.”).
102
Bruce Lehman, The Pharmaceutical Industry and the Patent System,
INTERNATIONAL INTELLECTUAL PROPERTY INSTITUTE (2003), http://users
.wfu.edu/mcfallta/DIR0/pharma_patents.pdf.
103
Id.
104
Roxanne Nelson, Pay-for-Delay Drug Deals: Do They Hurt or Help Patients?,
MEDSCAPE (Apr. 15, 2015), http://www.medscape.com/viewarticle/843231.
105
Id.
106
Diane Bartz, Controversial ‘pay-for-delay’ deals drop after FTC’s win in top
court, REUTERS (Jan. 13, 2016, 1:40PM), http://www.reuters.com/article/uspharmaceuticals-patent-ftc-idUSKCN0UR2JA20160113 (“In a typical pay-for-delay
deal, a branded drug company will give a generic firm money or some other
consideration in exchange for the generic firm’s agreement to delay bringing out a
cheaper version of the medicine.”).
107
Michael Hiltzik, The FDA can single-handedly reduce the drug price-gouging.
Why is it waiting?, LOS ANGELES TIMES (Jan. 5, 2016, 12:31PM), http://www.
latimes.com /business/hiltzik/la-fi-mh-the-fda-can-single-handedly-stop-2016010
101
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FDA approval process for generic pharmaceuticals reduces the
competition in the market and therefore, prices of brand-name
pharmaceuticals are not reduced. For these reasons, increasing the
number of generic pharmaceuticals on the market will not be an
effective way to reduce the price of pharmaceuticals.
Other reform proposals suggest allowing consumers to
import drugs from other countries.108 Given that the United States
pays more for prescription drugs than any other developed country,
this proposal seems attractive. However, the United States Federal
Food, Drug, and Cosmetic Act prohibits the interstate shipment,
including importation, of unapproved new drugs.109 In other words,
the importation of drugs that are not approved by the Food and
Drug Administration (FDA) violates the Food, Drug, and Cosmetic
Act except under certain circumstances.110 Unapproved drugs are
drugs, including foreign-made versions, that have not been
manufactured in accordance to FDA approval.111 However, as
previously mentioned in the EpiPen example, people in the United

5-column.html (“The FDA’s years-long backlog of approvals now runs to
thousands of drugs. Because of the backlog from previous years, of the nearly
1,600 applications for new generic drug approvals submitted in fiscal 2014, not a
single one was approved by the end of the fiscal year.”).
108
See Tironi, supra note 89.
109
21 U.S.C.S. § 331 (2016).
110
The FDA does not object to personal imports of drugs that the FDA
has not approved under certain circumstances such as, “[t]he drug is for a serious
condition for which effective treatment is not available in the United States; [t]here
is not commercialization or promotion of the drug to U.S. residents; [t]he drug is
considered not to represent an unreasonable risk; [t]he individual importing the
drug verifies in writing that it is for his or her own use, and provides contact
information for the doctor providing treatment or shows the product is for the
continuation of treatment begun in a foreign country; and [g]enerally, not more
than a 3-month supply of the drug is imported.” Is it legal for me to personally import
drugs?, U.S. FOOD AND DRUG ADMINISTRATION, http://www.fda.gov/AboutFDA
/Transparency/Basics/ucm194904.htm (last visited Nov. 13, 2017).
111
Under the Act the FDA may refuse admission of any drug that
“appears” to be unapproved. The burden is then on the person attempting to
import the drug to show that the drug is FDA approved. Marvin A. Blumberg,
Importation of Drugs, U.S. FOOD AND DRUG ADMINISTRATION, http://www.fda.gov
/forindustry/importprogram/ucm173751.htm (last visited Nov. 13, 2017).
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States often buy pharmaceuticals from foreign countries.112 A major
concern with drug importation is safety.113 People may think they are
buying an approved drug, when in reality they are buying a
counterfeit.114 Some additional safety concerns include incorrect
doses, contaminated pharmaceuticals, toxic ingredients, and
ineffectiveness. Further, federal regulators cannot guarantee where or
how drugs sold abroad were made.115 The FDA also has a limited
ability to take action against these foreign sellers.116 People buying
foreign pharmaceuticals must rely on the foreign governments to
inspect the pharmaceuticals. These foreign governments may not
inspect the pharmaceuticals as thoroughly as the United States
government. Legalizing the importation of pharmaceuticals from
foreign countries would create more problems than benefits.
VIII. CONCLUSION
In conclusion, Medicare should be allowed to negotiate
directly with brand-name pharmaceutical companies in order to
reduce the price of pharmaceuticals. Medicare should be allowed to
use their bargaining power to reduce the price of brand-name
pharmaceuticals. This comment described how Canada and the
United Kingdom have achieved lower prices for brand-name
pharmaceuticals and suggests that the United States should adopt
certain aspects of both Canada’s system and the United Kingdom’s
system to create an efficient, effective, and safe system for its citizens.
Pharmaceutical pricing is an extremely important issue that will affect

112

See Mohney, supra note 26.

Sally C. Pipes, Letting patients buy Canadian drugs will only import trouble,
THE HILL (Feb. 2, 2015, 1:00 PM), http://thehill.com/blogs/congressblog/healthcare/231320-letting-patients-buy-canadian-drugs-will-only-importtrouble.
115
Id. (explaining that purchasing brand-name pharmaceuticals from
foreign countries is not safe due to a lack of knowledge about the safety measures
in the foreign countries and a lack of knowledge about the chemical composition of
the foreign country’s pharmaceutical).
116
John M. Taylor, III, Importation of Prescription Drugs, Testimony before
the Permanent Subcommittee of Investigations Senate Committee on
Governmental Affairs, (July, 22, 2004).
114
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most people throughout their lifetime. No person should be
restricted from receiving proper treatment because they cannot
afford to buy the pharmaceuticals they need. Allowing Medicare to
negotiate directly with brand-name pharmaceutical companies is the
most effective way to cure the high costs of pharmaceuticals in
America.
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